ASTRAZENECA PLC ADR

NASDAQ: AZN (Astrazeneca PLC)

最近更新时间: 5天之前, 11:04AM

84.69

0.86 (1.03%)

  • 1天 1.03%
  • 5天 1.03%
  • 1月 12.38%
  • 6月 21.77%
  • 今年至今天 28.55%
  • 1年 11.58%
  • 5年 59.58%
前收盘价格 83.83
收盘价格 83.90
成交量 3,125,391
平均成交量 (3个月) 5,049,212
市值 262,582,976,512
市盈率 (P/E TTM) 31.96
预期市盈率 (P/E Forward) 16.31
价格/销量 (P/S) 4.63
股市价格/股市净资产 (P/B) 5.80
52周波幅
61.24 (-27%) — 86.57 (2%)
利润日期 6 Nov 2025
股息率 (DY TTM) 1.85%
营业毛利率 14.14%
营业利益率 (TTM) 27.94%
稀释每股收益 (EPS TTM) 2.48
季度收入增长率 (YOY) 7.20%
季度盈利增长率 (YOY) 33.80%
总债务/股东权益 (D/E MRQ) 77.11%
流动比率 (MRQ) 0.900
营业现金流 (OCF TTM) 13.09 B
杠杆自由现金流 (LFCF TTM) 9.35 B
资产报酬率 (ROA TTM) 8.16%
股东权益报酬率 (ROE TTM) 19.79%

市场趋势

短期 中期
行业 Drug Manufacturers - General (US) 看涨 看跌
Drug Manufacturers - General (全球的) 看涨 看跌
股票 Astrazeneca PLC 混合的 混合的

AIStockmoo 评分

0.8
分析师共识 2.0
内部交易活动 NA
价格波动 -3.0
技术平均移动指标 0.0
技术振荡指标 4.0
平均 0.75

相关股票

股票 市值 DY P/E（TTM） P/B
AZN 263 B 1.85% 31.96 5.80
SNY 120 B 4.60% 16.03 1.49
AMGN 161 B 3.14% 24.45 21.55
GILD 141 B 2.08% 23.78 6.97
GRFS 6 B 1.73% 28.00 1.12
BIIB 21 B - 13.64 1.29

A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, immunology and rare diseases. The majority of sales come from international markets with the United States representing close to one third of its sales.
部门 Healthcare
行业 Drug Manufacturers - General
投资方式 Large Growth
机构持股比例 17.13%

该时间范围内无数据。

该时间范围内无数据。

  • 3M
日期 类型 细节
19 Oct 2025 公告 DATROWAY® (datopotamab deruxtecan-dlnk) demonstrated unprecedented median overall survival improvement of five months vs. chemo as 1st-line treatment for patients with metastatic triple-negative breast cancer for whom immunotherapy was not an option
18 Oct 2025 公告 ENHERTU® (fam-trastuzumab deruxtecan-nxki) reduced the risk of disease recurrence or death by 53% vs. T-DM1 in patients with high-risk HER2-positive early breast cancer following neoadjuvant therapy in DESTINY-Breast05 Phase III trial
18 Oct 2025 公告 ENHERTU® (fam-trastuzumab deruxtecan-nxki) followed by THP before surgery resulted in a pathologic complete response in 67% of patients with high-risk HER2-positive early-stage breast cancer in DESTINY-Breast11 Phase III trial
17 Oct 2025 公告 IMFINZI® (durvalumab) regimen reduced the risk of disease recurrence or death by 32% in high-risk non-muscle-invasive bladder cancer in the POTOMAC Phase III trial
17 Oct 2025 公告 IMFINZI® (durvalumab)-based regimen reduced the risk of death by 22% in early gastric cancer vs. chemotherapy alone in MATTERHORN Phase III trial
17 Oct 2025 公告 TEZSPIRE approved in the US for chronic rhinosinusitis with nasal polyps
17 Oct 2025 CNBC Eli Lilly and Novo Nordisk stocks fall as Trump says he wants $150 price for GLP-1s
15 Oct 2025 公告 AstraZeneca unveils expanded manufacturing facility in Texas
13 Oct 2025 公告 AstraZeneca furthers ambition to redefine cancer care with first data from four major pivotal trials at ESMO
10 Oct 2025 CNBC Trump reaches deal with AstraZeneca to lower U.S. drug prices
09 Oct 2025 公告 AstraZeneca plans to increase investment and scope of its Virginia manufacturing facility to $4.5 billion, creating 3,600 new jobs
09 Oct 2025 公告 Turbine Launches Collaboration with AstraZeneca, Leveraging Turbine's Virtual Disease Models to Rationalize ADC Discovery
07 Oct 2025 公告 Baxdrostat met the primary endpoint in Bax24 Phase III trial in patients with resistant hypertension
06 Oct 2025 公告 DATROWAY® (datopotamab deruxtecan-dlnk) improved OS and PFS in TROPION-Breast02
29 Sep 2025 公告 ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated highly statistically significant and clinically meaningful improvement in invasive disease-free survival vs. T-DM1 in DESTINY-Breast05 Phase III trial
26 Sep 2025 公告 AstraZeneca launches direct-to-consumer platform to expand access to medications for US patients, including those living with chronic conditions
24 Sep 2025 公告 ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab granted Priority Review in the US as 1st-line treatment for patients with HER2-positive metastatic breast cancer
22 Sep 2025 公告 SOPHiA GENETICS Expands Collaboration with AstraZeneca to Enhance Detection of Breast and Prostate Cancer
18 Sep 2025 公告 AIRSUPRA® (albuterol/budesonide) US prescribing information updated to reflect the statistically significant severe exacerbation risk reduction in patients with mild asthma compared with albuterol
17 Sep 2025 公告 Advancing Cancer Research Brings New Hope for Patients Worldwide
17 Sep 2025 公告 SAPHNELO self-administration TULIP-SC Phase III trial meets primary endpoint in patients with systemic lupus erythematosus based on an interim analysis
07 Sep 2025 公告 TAGRISSO® (osimertinib) plus chemotherapy demonstrated a median overall survival of nearly four years, the longest benefit ever reported in a global Phase III trial in EGFR-mutated advanced lung cancer
30 Aug 2025 公告 Baxdrostat demonstrated statistically significant and clinically meaningful reduction in systolic blood pressure in patients with hard-to-control hypertension in the BaxHTN Phase III ​trial
24 Aug 2025 CNBC Eli Lilly's obesity pill remains a viable rival to Novo's oral Wegovy despite data that underwhelmed investors
15 Aug 2025 公告 FLUMIST (Influenza, Vaccine Live, Intranasal), the nation’s only nasal spray flu vaccine, now available for home delivery
13 Aug 2025 公告 The Healthcare Businesswomen's Association (HBA) Honors AstraZeneca and Viseven with 2025 ACE Awards for Workforce Innovation and Global Impact
07 Aug 2025 CNBC Eli Lilly shares drop after obesity pill shows modest late-stage trial results
05 Aug 2025 公告 SOPHiA GENETICS expands collaboration with AstraZeneca using AI to improve breast cancer patient outcomes
31 Jul 2025 CNBC Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days
29 Jul 2025 公告 AstraZeneca results: H1 and Q2 2025
28 Jul 2025 公告 IMFINZI® (durvalumab) granted Priority Review and Breakthrough Therapy Designation in the US for patients with resectable early-stage gastric and gastroesophageal junction cancers
显示更多
股息率 (DY TTM) 1.85%
5年平均股息收益率 2.35%
股息支付比率 62.37%
预计下次股息支付 Mar 2026
除息日 公告日期 支付日期 详情
08 Aug 2025 29 Jul 2025 08 Sep 2025 0.515 现金
21 Feb 2025 06 Feb 2025 24 Mar 2025 1.05 现金
09 Aug 2024 25 Jul 2024 09 Sep 2024 0.5 现金
22 Feb 2024 08 Feb 2024 25 Mar 2024 0.985 现金
10 Aug 2023 28 Jul 2023 11 Sep 2023 0.465 现金
23 Feb 2023 09 Feb 2023 27 Mar 2023 0.985 现金
11 Aug 2022 29 Jul 2022 12 Sep 2022 0.465 现金
24 Feb 2022 10 Feb 2022 28 Mar 2022 0.985 现金
12 Aug 2021 29 Jul 2021 13 Sep 2021 0.45 现金
25 Feb 2021 11 Feb 2021 29 Mar 2021 0.95 现金
13 Aug 2020 30 Jul 2020 14 Sep 2020 0.45 现金
27 Feb 2020 14 Feb 2020 30 Mar 2020 0.95 现金
08 Aug 2019 29 Jul 2019 09 Sep 2019 0.45 现金
28 Feb 2019 14 Feb 2019 27 Mar 2019 0.95 现金
09 Aug 2018 26 Jul 2018 10 Sep 2018 0.45 现金
15 Feb 2018 02 Feb 2018 19 Mar 2018 0.95 现金
09 Aug 2017 28 Jul 2017 11 Sep 2017 0.45 现金
15 Feb 2017 02 Feb 2017 20 Mar 2017 0.95 现金
10 Aug 2016 28 Jul 2016 12 Sep 2016 0.45 现金
17 Feb 2016 05 Feb 2016 21 Mar 2016 0.95 现金
12 Aug 2015 30 Jul 2015 14 Sep 2015 0.45 现金
18 Feb 2015 09 Feb 2015 23 Mar 2015 1.9 现金
13 Aug 2014 31 Jul 2014 15 Sep 2014 0.9 现金
19 Feb 2014 07 Feb 2014 24 Mar 2014 1.9 现金
14 Aug 2013 01 Aug 2013 16 Sep 2013 0.9 现金
13 Feb 2013 31 Jan 2013 18 Mar 2013 1.9 现金
08 Aug 2012 26 Jul 2012 10 Sep 2012 0.9 现金
15 Feb 2012 02 Feb 2012 19 Mar 2012 1.95 现金
04 Aug 2011 28 Jul 2011 12 Sep 2011 0.85 现金
02 Feb 2011 27 Jan 2011 14 Mar 2011 1.85 现金
04 Aug 2010 29 Jul 2010 13 Sep 2010 0.7 现金
03 Feb 2010 28 Jan 2010 15 Mar 2010 1.71 现金
05 Aug 2009 30 Jul 2009 14 Sep 2009 0.59 现金
04 Feb 2009 29 Jan 2009 16 Mar 2009 1.5 现金
06 Aug 2008 31 Jul 2008 15 Sep 2008 0.55 现金
07 Feb 2008 04 Feb 2008 17 Mar 2008 1.35 现金
08 Aug 2007 27 Jul 2007 17 Sep 2007 0.52 现金
07 Feb 2007 01 Feb 2007 19 Mar 2007 1.23 现金
09 Aug 2006 27 Jul 2006 18 Sep 2006 0.49 现金
08 Feb 2006 02 Feb 2006 20 Mar 2006 0.92 现金
10 Aug 2005 29 Jul 2005 19 Sep 2005 0.38 现金
09 Feb 2005 27 Jan 2005 21 Mar 2005 0.645 现金
11 Aug 2004 22 Jul 2004 20 Sep 2004 0.295 现金
显示更多

每年股息收益率

年份 每年总股息 ($) 频率/年份 收益率 %
2025 1.57 2 1.85
2024 1.49 2 2.27
2023 1.45 2 2.15
2022 1.45 2 2.14
2021 1.40 2 2.40
2020 1.40 2 2.80
2019 1.40 2 2.81
2018 1.40 2 3.69
2017 1.40 2 4.04
2016 1.40 2 5.12
2015 2.35 2 6.92
2014 2.80 2 7.96
2013 2.80 2 9.43
2012 2.85 2 12.06
2011 2.70 2 11.67
2010 2.41 2 10.44
2009 2.09 2 8.91
2008 1.90 2 9.26
2007 1.75 2 8.17
2006 1.41 2 5.27
2005 1.03 2 4.22
2004 0.295 1 1.62
显示更多

支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。

投资组合

AI 建议策略模板

自定义的价格提醒

风险概况

| | | | |
很保守
适度保守
中等
中等风险
激进风险
安全边际 (EP)
部分利润 (TP1)
目标利润 (TP2)
最大损失 (SL)

免责声明：以上内容仅供参考，并非投资建议。请咨询合格的财务顾问。

开始购买价格 (EP)

第一个目标价格赚取利润 (TP1)

第二个目标价格赚取利润 (TP2)

停止损失价格 (SL)

52周波幅范围
 
52WL
 
52WH
SL
EP
TP1
TP2

所有提醒价格都在52周波幅范围内

已实现利润 -
未实现利润 -
收到股息 2025 -
利润总额 -
平均回报 -
数量(购买) -
平均价格(购买) -
数量(卖出) -
平均价格(卖出) -
没有符合您标准的股票